UroGen Pharma’s CMO Trades 6,363 Shares to Cover Taxes—No Red Flag for Investors
UroGen insider selling: Mark Schoenberg’s tax‑coverage trades are routine, not a red flag—yet his ongoing buying shows confidence in the company’s uro‑oncology pipeline.
3 minutes to read